about
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesisRecent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents.Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects.Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization.Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents.Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands.Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(heteroarylmethyl)indol-3-ylglyoxylamides.3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.Dialkylaminoalkylindolonaphthyridines as potential antitumour agents: synthesis, cytotoxicity and DNA binding properties.Synthesis, in vitro antiproliferative activity and DNA-interaction of benzimidazoquinazoline derivatives as potential anti-tumor agents.Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships.Geometrically constrained analogues of N-benzylindolylglyoxylylamides: [1, 2, 4]triazino[4, 3-a]benzimidazol-4(10H)-one derivatives as potential new ligands at the benzodiazepine receptor.Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the gamma-aminobutyric acid-A (GABAA) alpha2 benzodiazepine receptor.Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.Synthesis and benzodiazepine receptor affinity of derivatives of the new tricyclic heteroaromatic system pyrido[3',2':5,6]thiopyrano[4,3-c]pyridazin-3(2H,5H)-one.Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors.5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.Synthesis, structure-activity relationships, and molecular modeling studies of N-(indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor.3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit α- and β-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 IsoformsDeepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamidesBenzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling StudiesBenzothiopyranoindole-Based Antiproliferative Agents: Synthesis, Cytotoxicity, Nucleic Acids Interaction, and Topoisomerases Inhibition PropertiesPyrido[1,2-a]pyrimidin-4-one Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors Exhibiting Antioxidant ActivitySpecific inhibition of benzodiazepine receptor binding by some N-(indol-3-ylglyoxylyl) amino acid derivatives: stereoselective interactionsSynthesis andin vitroantiproliferative activity of new substituted benzo[3′,2′:5,6]thiopyrano[4,3-d]pyrimidinesIndole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonistsMitochondrial permeability transition induced by novel pyridothiopyranopyrimidine derivatives: Potential new antimitochondrial antitumour agentsSynthesis, DNA binding and in vitro antiproliferative activity of purinoquinazoline, pyridopyrimidopurine and pyridopyrimidobenzimidazole derivatives as potential antitumor agentsN-(Indol-3-ylglyoxylyl)methionine derivatives: preparation and gastric anti-secretory activity
P50
Q28291960-714ED37E-EB98-4D1B-A900-6C814E5ADF3BQ34143010-02D45BD5-231F-47A1-8B38-1CFEA954FD0EQ37695391-2891C339-D11A-4925-AEF2-FD3A2BE0952CQ37971991-14C16D86-61DC-44D9-8F1F-B994ABF7EBA1Q37971994-D7F446B6-8D3E-455C-9425-AC598CAB4643Q38839883-C855B74D-5FBE-41D7-968D-E3B636CBAB89Q39032395-B76CECC1-120E-43EC-8BF2-F82CFC5EA63CQ39708231-A78EE29D-2014-46D3-ABAA-C9F5BA189A61Q39712416-5B63E6CE-3BEE-4464-A71E-FA1D1EF76F60Q39913911-23623741-2C18-4A9D-8910-22AD76136A05Q40163832-56C13762-FB12-4B26-8943-185AD177597FQ40293381-2D3A7367-2063-4DD1-ABA4-D1A4E8942102Q40696312-9C54BA13-3AF0-4EE0-B16A-EBBF844C8747Q40707457-D94D0EC3-A14F-4117-B061-D00995E04BF1Q43642507-6AFDA7EC-8BE1-44BC-B1EF-65812BF16D79Q43655332-83A200F4-2012-4827-B917-6A0F70E7EA36Q44607871-7D22AFBA-9385-4449-A4CA-FE2825A85F17Q45788712-61ACF936-B985-41DF-978D-8E409557D5F6Q45996569-B6CFAE5F-615C-4D05-AFF2-C18C16923834Q46117787-0355F13E-5D13-4905-83A8-F32C09083CCFQ46411651-33E4B6FF-19D9-41E5-ACFC-AC0BC0286A94Q46615145-43C76973-CB44-4EC3-BD23-A3FA9F13A59EQ46633280-73B20ECA-72B3-4FAB-9EAA-EC89516DCAA0Q46775756-794F9F53-637F-40C9-AE6E-753097E11507Q46957934-37B446A6-9841-4C9B-BF01-486403829B0EQ48390084-8A595AE9-A8D1-4D94-B6FA-651E9189F5A7Q48828417-4BF7D156-F351-402C-9A02-D64AD4689587Q51761799-2D66847D-AF3D-4F12-B2F0-8D8390F5215EQ58308152-F164734A-38CE-4DBC-BDA1-12982C4D17D2Q58855652-8923D308-966E-4296-9108-D483BF84B939Q58855699-511C1B00-49AC-4AAC-AE95-7742DA36DB5AQ58855736-7719C164-34DA-471B-8D74-A262B22C2D20Q58855767-C1763956-B754-4003-9EF9-174600775ED1Q59033822-281E7BF1-4D86-450B-BD02-AFD0B1C07659Q59171635-29F89403-9F3E-4082-9472-CAE13A01AC00Q59171694-687F2B85-1B01-42E5-AC79-2CCF20FA1C9AQ59647253-4F5F305D-BDEA-4BC7-BF0D-C1C44CB42792Q59647265-65F66076-E86A-4DE4-9E40-587F449CDDCCQ59647272-B8B97D6B-3F3B-4631-9F46-1AE6BF924972
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anna Maria Marini
@ast
Anna Maria Marini
@en
Anna Maria Marini
@es
Anna Maria Marini
@nl
Anna Maria Marini
@sl
type
label
Anna Maria Marini
@ast
Anna Maria Marini
@en
Anna Maria Marini
@es
Anna Maria Marini
@nl
Anna Maria Marini
@sl
altLabel
A M Marini
@en
prefLabel
Anna Maria Marini
@ast
Anna Maria Marini
@en
Anna Maria Marini
@es
Anna Maria Marini
@nl
Anna Maria Marini
@sl
P106
P1153
35553619000
P21
P31
P496
0000-0001-8664-375X